Radius Health To Be Acquired By Gurnet Point Capital & Patient Square Capital

Pharmaceutical company Radius Health, Inc. entered into a definitive agreement to be acquired by Gurnet Point Capital (Gurnet Point) and Patient Square Capital (Patient Square) in a transaction valued at approximately $890 million. Gurnet Point and Patient Square will assume Radius Health's debt and assume responsibility for paying the Contingent Value Right (CVR) for Radius Health's lead product, TYMLOS® (abaloparatide), an injection for postmenopausal women with osteoporosis at high risk for fracture. Debt financing for this transaction will be provided by OrbiMed Advisors, LLC. The transaction is slated to close in the third quarter of 2022. Following the . . .